Simeprevir is now available for Hepatitis C patients in Japan, USA and Canada

Stockholm, Sweden—Medivir AB (OMX: MVIR) Based on the recent approvals in Japan,
Canada and USA, simeprevir is now available in all three markets. Simeprevir is
administered once-daily for 12 weeks in combination with pegylated interferon
and ribavirin, followed by pegylated interferon and ribavirin alone for an
additional 12 or 36 weeks.

For more information please contact:
Rein Piir, EVP Corporate Affairs & IR, mobile: +46 708 537 292

Medivir is required under the Securities Markets Act to make the information in
this press release public. The information was submitted for publication at 8.30
a.m. CET on 10 December 2013.

About Simeprevir
Simeprevir is an NS3/4A protease inhibitor jointly developed by Janssen R&D
Ireland and Medivir AB for the treatment of chronic hepatitis C infection in
combination with other antivirals in HCV genotype 1 & 4 infected patients with
compensated liver disease, including cirrhosis.

Simeprevir was approved for the treatment of genotype 1 hepatitis C in September
2013 in Japan and in the USA and Canada in November and has now been launched in
all three markets. A Marketing Authorisation Application was submitted to the
European Medicines Agency (EMA) in April 2013 by Janssen-Cilag International NV
seeking approval of simeprevir for the treatment of genotype 1 or genotype 4
chronic hepatitis C.

To date, more than 3,700 patients have been treated with simeprevir in clinical
trials. Simeprevir is also being studied in several interferon-free regimens
using selected combinations of direct-acting antiviral agents with different
mechanisms of action.

About Medivir
Medivir is an emerging research-based pharmaceutical company focused on
infectious diseases. Medivir has world class expertise in polymerase and
protease drug targets and drug development which has resulted in a strong
infectious disease R&D portfolio. The Company’s key pipeline asset is
simeprevir, a novel protease inhibitor for the treatment of hepatitis C that is
being developed in collaboration with Janssen R&D Ireland. The company is also
working with research and development in other areas, such as bone disorders and
neuropathic pain. Medivir has also a broad product portfolio with prescription
pharmaceuticals in the Nordics.

For more information about Medivir AB, please visit the Company’s website:
www.medivir.com

Medivir is a collaborative and agile pharmaceutical company with an R&D focus on
infectious diseases and a leading position in hepatitis C. We are passionate and
uncompromising in our mission to develop and commercialize innovative
pharmaceuticals that improve people’s health and quality of life.